New GOBOLDLY Ad Showcases Need to Foster America's Leadership in Medical Innovation

WASHINGTON, Feb. 25, 2019 /PRNewswire/ -- Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released Breakthrough, the latest chapter of GOBOLDLY advertising showcasing the extraordinary medical breakthroughs being discovered and the need to protect America's leadership in medical innovation.

In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat some of the most challenging diseases, including cancer, asthma and autoimmune conditions.

For example, in 2017, the U.S. Food and Drug Administration approved the first two CAR-T therapies that treat certain types of cancer by training white blood cells to detect cancer cells. The first gene therapy was also approved in 2017, which cures an inherited form of blindness. 

As a result of each new medical advancement, cancer death rates in the United States have declined 27 percent since peaking in 1991. Approximately 73 percent of these survival gains are attributable to innovative treatments, including new medicines. 

The competitive marketplace in the United States that encourages continued medical innovation is why the country leads the world in the development of new treatments and cures. For example, Americans can access cancer medicines about two years earlier, on average, than patients in other developed countries such as the United Kingdom, Germany and France. 

With more than 7,000 medicines in development, we are in one of the greatest eras of scientific innovation with the potential to save and improve millions of lives. We must ensure the policy and regulatory environment in the United States encourages continued medical progress, rather than stand in its way. That's why we're committed to advocating for the latest innovations and protecting future innovations. We continue to go boldly, together.

Learn more about the researchers, patients and breakthroughs in progress at www.innovation.org.

This post originally appeared on the PhRMA Catalyst blog.

Holly Campbell
[email protected] 
202-835-3460

SOURCE Pharmaceutical Research and Manufacturers of America (PhRMA)